March 11, 2020 / 6:58 AM / a month ago

BRIEF-Nicox Updates Agreement With Ocumension Therapeutics On ZERVIATE

March 11 (Reuters) - NICOX SA:

* OCUMENSION’S ZERVIATE EXCLUSIVE RIGHTS EXPANDED TO INCLUDE SOUTH EASTERN ASIAN COUNTRIES

* NICOX UPDATES ON ZERVIATE PROGRESS IN CHINA AND EXPANDS THE COUNTRIES OF ITS AGREEMENT WITH OCUMENSION THERAPEUTICS

* OCUMENSION PREPARING TO FILE AN IND WITH CHINESE CDE (CENTER FOR DRUG EVALUATION) FOR A CLINICAL STUDY EXPECTED TO START IN Q4 2020

* NICOX MAY POTENTIALLY RECEIVE DEVELOPMENT AND SALES MILESTONES OF UP EUR 17 MILLION TOGETHER WITH TIERED ROYALTIES OF BETWEEN 5% AND 9% ON SALES OF ZERVIATE Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below